The stock of PhaseRx Inc (NASDAQ:PZRX) is a huge mover today! About 194,806 shares traded hands or 1410.12% up from the average. PhaseRx Inc (NASDAQ:PZRX) has risen 6.00% since September 3, 2016 and is uptrending. It has underperformed by 6.22% the S&P500.
The move comes after 9 months positive chart setup for the $37.49M company. It was reported on Oct, 3 by Barchart.com. We have $6.51 PT which if reached, will make NASDAQ:PZRX worth $48.74M more.
Analysts await PhaseRx Inc (NASDAQ:PZRX) to report earnings on November, 1. After $-0.59 actual EPS reported by PhaseRx Inc for the previous quarter, Wall Street now forecasts -66.10% EPS growth.
According to Zacks Investment Research, “PhaseRx, Inc. is a preclinical biopharmaceutical company. It is engaged in developing products for the treatment of inherited enzyme deficiencies in the liver using intracellular enzyme replacement therapy. The Company’s i-ERT approach is enabled by its proprietary Hybrid mRNA Technology(TM) platform. PhaseRx, Inc. is headquartered in Seattle, Wash.”
More notable recent PhaseRx Inc (NASDAQ:PZRX) news were published by: Marketwatch.com which released: “PhaseRx Inc.” on May 18, 2016, also Prnewswire.com with their article: “PhaseRx to Present at the 2016 Aegis Growth Conference” published on September 14, 2016, Prnewswire.com published: “PhaseRx Appoints Peggy Phillips to Board of Directors” on August 22, 2016. More interesting news about PhaseRx Inc (NASDAQ:PZRX) were released by: Prnewswire.com and their article: “PhaseRx Announces Pricing of Initial Public Offering” published on May 18, 2016 as well as Prnewswire.com‘s news article titled: “PhaseRx Advances Product Pipeline for Treatment of Rare Genetic Liver Diseases” with publication date: June 21, 2016.
PZRX Company Profile
PhaseRx, Inc. is a preclinical biopharmaceutical company. The Firm develops a portfolio of products for the treatment of inherited enzyme deficiencies in the liver, using intracellular enzyme replacement therapy, i-ERT. The Company’s i-estrogen replacement therapy (ERT) approach is enabled by its Hybrid messenger ribonucleic acid (RNA), or messenger ribonucleic acid (mRNA), Technology platform, which allows synthesis of the missing enzyme inside the cell. The Company’s product portfolio consists of approximately three urea cycle disorders, which include ornithine transcarbamylase deficiency (OTCD), argininosuccinate lyase (ASL) deficiency and argininosuccinate synthetase (ASS1) deficiency.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.